The U.S. Food and Drug Administration (FDA) has granted andecaliximab a Rare Pediatric Disease Designation (RPDD) for the treatment of FOP. An RPDD designation is granted to potential treatments for ...
Trial aims to establish safety and provide proof of concept for GYS1 inhibition as promising new treatment strategy in patients with late-onset Pompe disease ...
DURHAM, NC, USA I2, 2025 I IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human ...
NORTH CHICAGO, IL and SAN DIEGO, CA, USA I3, 2025 I AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and ...
CAMBRIDGE, MA, USA & BRISBANE, Australia I2, 2025 I Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density ...
Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a ...
About Cullgen Inc. Cullgen is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective ...
Novel breakthrough: first molecule to modulate the fundamental mechanism of T cell activation underlying autoimmune pathology ...
GAITHERSBURG, MD, USA I2, 2025 I Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today ...
NEWTOWN SQUARE, PA, USA and SHANGHAI, China I1, 2025 I ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP) a clinical-stage company ...
SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination ...
Following U.S. FDA Priority Review, approval is based on data demonstrating SPRAVATO® alone met its primary endpoint at 4 weeks and led to rapid and superior ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback